Tags

Type your tag names separated by a space and hit enter

A Comparison of New Pharmacological Agents for the Treatment of Obesity.
Ann Pharmacother. 2016 May; 50(5):376-88.AP

Abstract

OBJECTIVE

To review and compare the phase 3 clinical trial evidence on the 4 new pharmacological agents approved for the management of overweight and obesity.

DATA SOURCES

Searches were performed (from 1966 through January 2016) in PubMed/MEDLINE, Scientific Citation Index, and product package inserts to identify key phase 3 clinical trials that were used in the approval of each agent.

STUDY SELECTION AND DATA EXTRACTION

Phase 3 clinical trials that listed end points of ≥5% and ≥10% weight loss benchmarks from baseline as well as total percentage of weight loss by participants were selected for the review.

DATA SYNTHESIS

No head-to-head trials have been identified between these agents at this point, which limits comparisons across agents. Phentermine/topiramate ER appeared to have the best overall average weight loss from baseline as well as highest percentages of patients achieving both ≥5% and ≥10% weight loss benchmarks, followed second by naltrexone/bupropion, and then liraglutide, with lorcaserin showing the lowest rates. Phentermine/topiramate ER completion rates were highest for both treatment and placebo groups, followed by liraglutide, with lorcaserin and naltrexone/bupropion showing similar completion rates, below that of the other 2 agents. Common side effects reported differed between agents, although the most common adverse events reported were gastrointestinal in nature, with liraglutide demonstrating the highest reported rates and lorcaserin demonstrating the lowest.

CONCLUSION

These 4 new pharmacological agents represent new options for the clinician to utilize when trying to manage the problem of obesity. No clear first-line agent has emerged, so treatment decisions should be based on patient-specific factors.

Authors+Show Affiliations

University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA Wesley.Nuffer@ucdenver.edu.University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

26887340

Citation

Nuffer, Wesley, et al. "A Comparison of New Pharmacological Agents for the Treatment of Obesity." The Annals of Pharmacotherapy, vol. 50, no. 5, 2016, pp. 376-88.
Nuffer W, Trujillo JM, Megyeri J. A Comparison of New Pharmacological Agents for the Treatment of Obesity. Ann Pharmacother. 2016;50(5):376-88.
Nuffer, W., Trujillo, J. M., & Megyeri, J. (2016). A Comparison of New Pharmacological Agents for the Treatment of Obesity. The Annals of Pharmacotherapy, 50(5), 376-88. https://doi.org/10.1177/1060028016634351
Nuffer W, Trujillo JM, Megyeri J. A Comparison of New Pharmacological Agents for the Treatment of Obesity. Ann Pharmacother. 2016;50(5):376-88. PubMed PMID: 26887340.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A Comparison of New Pharmacological Agents for the Treatment of Obesity. AU - Nuffer,Wesley, AU - Trujillo,Jennifer M, AU - Megyeri,Jade, Y1 - 2016/02/17/ PY - 2016/2/19/entrez PY - 2016/2/19/pubmed PY - 2016/11/1/medline KW - drug treatment KW - obesity KW - overweight KW - pharmacotherapy KW - weight loss SP - 376 EP - 88 JF - The Annals of pharmacotherapy JO - Ann Pharmacother VL - 50 IS - 5 N2 - OBJECTIVE: To review and compare the phase 3 clinical trial evidence on the 4 new pharmacological agents approved for the management of overweight and obesity. DATA SOURCES: Searches were performed (from 1966 through January 2016) in PubMed/MEDLINE, Scientific Citation Index, and product package inserts to identify key phase 3 clinical trials that were used in the approval of each agent. STUDY SELECTION AND DATA EXTRACTION: Phase 3 clinical trials that listed end points of ≥5% and ≥10% weight loss benchmarks from baseline as well as total percentage of weight loss by participants were selected for the review. DATA SYNTHESIS: No head-to-head trials have been identified between these agents at this point, which limits comparisons across agents. Phentermine/topiramate ER appeared to have the best overall average weight loss from baseline as well as highest percentages of patients achieving both ≥5% and ≥10% weight loss benchmarks, followed second by naltrexone/bupropion, and then liraglutide, with lorcaserin showing the lowest rates. Phentermine/topiramate ER completion rates were highest for both treatment and placebo groups, followed by liraglutide, with lorcaserin and naltrexone/bupropion showing similar completion rates, below that of the other 2 agents. Common side effects reported differed between agents, although the most common adverse events reported were gastrointestinal in nature, with liraglutide demonstrating the highest reported rates and lorcaserin demonstrating the lowest. CONCLUSION: These 4 new pharmacological agents represent new options for the clinician to utilize when trying to manage the problem of obesity. No clear first-line agent has emerged, so treatment decisions should be based on patient-specific factors. SN - 1542-6270 UR - https://www.unboundmedicine.com/medline/citation/26887340/A_Comparison_of_New_Pharmacological_Agents_for_the_Treatment_of_Obesity_ L2 - http://journals.sagepub.com/doi/full/10.1177/1060028016634351?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -